Dermbits

Welcome to Dermbits! Watch short videos of KOLs answering your questions

Dr Bhutani-Jacques on Psoriasis (October 2026)

Dr Bhutani-Jacques on Psoriasis (October 2026)

Dr Dorizas on Actinic Keratosis (October 2026)

Dr Dorizas on Actinic Keratosis (October 2026)

When clinicians and patients have different priorities around how a treatment is administered, how do you navigate that conversation?

Oct 2, 2026Psoriasis

When clinicians and patients have different priorities around how a treatment is administered, how do you navigate that conversation?

-

When patients are doing well on biologic therapy, how do you maintain meaningful clinical engagement without creating unnecessary treatment burden?

Oct 2, 2026Psoriasis

When patients are doing well on biologic therapy, how do you maintain meaningful clinical engagement without creating unnecessary treatment burden?

-

What assumptions do clinicians sometimes make about patients' preference for self-administration that don't necessarily hold true in practice?

Oct 2, 2026Psoriasis

What assumptions do clinicians sometimes make about patients' preference for self-administration that don't necessarily hold true in practice?

-

What does HCP administration allow you to know about a patient's treatment that can be harder to assess with a self-administered biologic?

Oct 2, 2026Psoriasis

What does HCP administration allow you to know about a patient's treatment that can be harder to assess with a self-administered biologic?

-

What have you learned from patients who seemed well suited to self-administration initially but encountered challenges once treatment was underway?

Oct 2, 2026Psoriasis

What have you learned from patients who seemed well suited to self-administration initially but encountered challenges once treatment was underway?

-

When you're considering tildrakizumab for a patient with psoriasis, how does its HCP-administered model factor into your treatment decision?

Oct 2, 2026Psoriasis

When you're considering tildrakizumab for a patient with psoriasis, how does its HCP-administered model factor into your treatment decision?

-

What tends to cause clinicians or patients to fall into a reactive pattern of treating AKs as they appear rather than developing a longer-term management strategy?

Oct 1, 2026Actinic Keratosis

What tends to cause clinicians or patients to fall into a reactive pattern of treating AKs as they appear rather than developing a longer-term management strategy?

-

What do you try to understand when a patient who would benefit from field therapy is reluctant to move forward with treatment?

Oct 1, 2026Actinic Keratosis

What do you try to understand when a patient who would benefit from field therapy is reluctant to move forward with treatment?

-

What should clinicians know about cash-pay or network pharmacy pathways for Medicare patients who have been prescribed tirbanibulin?

Oct 1, 2026Actinic Keratosis

What should clinicians know about cash-pay or network pharmacy pathways for Medicare patients who have been prescribed tirbanibulin?

-

Can you describe a patient who was reluctant to undergo field therapy again after a difficult previous experience and how tirbanibulin affected your treatment approach?

Oct 1, 2026Actinic Keratosis

Can you describe a patient who was reluctant to undergo field therapy again after a difficult previous experience and how tirbanibulin affected your treatment approach?

-

Have younger patients presented different priorities or concerns around field therapy that have influenced your decision to use tirbanibulin?

Oct 1, 2026Actinic Keratosis

Have younger patients presented different priorities or concerns around field therapy that have influenced your decision to use tirbanibulin?

-

What has led you to consider tirbanibulin earlier in AK management rather than reserving field therapy for patients with more extensive disease?

Oct 1, 2026Actinic Keratosis

What has led you to consider tirbanibulin earlier in AK management rather than reserving field therapy for patients with more extensive disease?

-

How do you discuss infection-related concerns with patients who may be hesitant about starting tildrakizumab?

Sep 4, 2026Psoriasis

How do you discuss infection-related concerns with patients who may be hesitant about starting tildrakizumab?

-

What have you learned from patients who have remained on tildrakizumab long term?

Sep 4, 2026Psoriasis

What have you learned from patients who have remained on tildrakizumab long term?

-

When you're evaluating a medically complex patient with psoriasis, where does tildrakizumab fit into your treatment decision-making?

Sep 4, 2026Psoriasis

When you're evaluating a medically complex patient with psoriasis, where does tildrakizumab fit into your treatment decision-making?

-

How have conversations with oncologists or other specialists influenced your approach to treating psoriasis in patients with a history of malignancy?

Sep 4, 2026Psoriasis

How have conversations with oncologists or other specialists influenced your approach to treating psoriasis in patients with a history of malignancy?

-

What role does long-term safety experience play when you're choosing among multiple appropriate biologic options?

Sep 4, 2026Psoriasis

What role does long-term safety experience play when you're choosing among multiple appropriate biologic options?

-

Are there patients you consider medically complex who might not fit the traditional definition?

Sep 4, 2026Psoriasis

Are there patients you consider medically complex who might not fit the traditional definition?

-

How do you decide when a chronic disease is well controlled enough versus when additional improvement should still be pursued?

Sep 1, 2026Psoriasis

How do you decide when a chronic disease is well controlled enough versus when additional improvement should still be pursued?

-

When patients and clinicians define treatment success for psoriasis differently, how do you navigate those conversations?

Sep 1, 2026Psoriasis

When patients and clinicians define treatment success for psoriasis differently, how do you navigate those conversations?

-

Have you found that patient satisfaction and clinical response always align when evaluating treatment success with apremilast?

Sep 1, 2026Psoriasis

Have you found that patient satisfaction and clinical response always align when evaluating treatment success with apremilast?

-

What factors make you comfortable continuing apremilast in a patient who has improved but not achieved complete clearance?

Sep 1, 2026Psoriasis

What factors make you comfortable continuing apremilast in a patient who has improved but not achieved complete clearance?

-

How do you determine whether a patient is benefiting enough from apremilast to continue therapy rather than pursue a different option?

Sep 1, 2026Psoriasis

How do you determine whether a patient is benefiting enough from apremilast to continue therapy rather than pursue a different option?

-

Are there patients who technically qualify for more aggressive therapy but whom you still consider for apremilast? Why?

Sep 1, 2026Psoriasis

Are there patients who technically qualify for more aggressive therapy but whom you still consider for apremilast? Why?

-